Skip Navigation

Vaccine Safety Bibliography - April 2013

1.   Early estimates of seasonal influenza vaccine effectiveness-United States, January 2013. Am J Transplant. 2013 Mar; 13(3):811-4.

2.   How Brazil joined the quest for a yellow fever vaccine. Bull World Health Organ. 2013 Mar 1; 91(3):165-6.

3.   Pandemic vaccines and small excess of Guillain-Barre cases. BMJ. 2013 Mar 20;346:f1714.

4.   Protecting university students in the UK against meningococcal disease: vaccination is the way forward. Perspect Public Health. 2013 Mar; 133(2):90-1.

5.   Secondary and tertiary transmission of vaccinia virus after sexual contact with a smallpox vaccinee - san diego, california, 2012. MMWR Morb Mortal Wkly Rep. 2013 Mar 1; 62:145-7.

6.   Agarwal S. Economic evaluation of a pneumococcal vaccine in a high-risk population. Thorax. 2013 Mar 14. [Epub ahead  of print].

7.   Ali H, Guy RJ, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Donovan B. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis. 2013 Mar 18; 13:140.

8.   Ambrose CS, Toback SL. Improved timing of availability and administration of  influenza vaccine through the US Vaccines for Children Program from 2007 to 2011. Clin Pediatr (Phila). 2013 Mar; 52(3):224-30.

9.   Andersen A, Roth A, Jensen KJ, Erikstrup C, Lisse IM, Whittle H, Sartono E, Yazdanbakhsh M, Aaby P, Benn CS. The immunological effect of revaccination with Bacille Calmette-Guérin vaccine at 19 months of age. Vaccine. 2013 Mar 6. [Epub ahead of print].

10.  Anderson EJ, Shippee DB, Weinrobe MH, Davila MD, Katz BZ, Reddy S, Cuyugan MG, Lee SY, Simons YM, Yogev R, Noskin GA. Indirect protection of adults from rotavirus by pediatric rotavirus vaccination. Clin Infect Dis. 2013 Mar; 56(6):755-60.

11.  Ankrah DN, Mantel-Teeuwisse AK, De Bruin ML, Amoo PK, Ofei-Palm CN, Agyepong  I, Leufkens HG. Incidence of Adverse Events Among Healthcare Workers Following H1N1 Mass Immunization in Ghana : A Prospective Study. Drug Saf. 2013 Mar 19. [Epub ahead of print].

12.  Ashbaugh AR, Herbert CF, Saimon E, Azoulay N, Olivera-Figueroa L, Brunet A. The Decision to Vaccinate or Not during the H1N1 Pandemic: Selecting the Lesser of Two Evils? PLoS One. 2013;8(3):e58852.

13.  Ateudjieu J, Kenfack B, Wakam Nkontchou B, Demanou M. Program on immunization and cold chain monitoring: the status in eight health districts in Cameroon. BMC Res Notes. 2013 Mar 16;6(1):101. [Epub ahead of print].

14.  Bae EY, Choi UY, Kwon HJ, Jeong DC, Rhim JW, Ma SH, Lee KI, Kang JH. The Immunogenicity and Safety of Inactivated Trivalent Split Influenza Vaccine in Young Children with Recurrent Wheezing. Clin Vaccine Immunol. 2013 Mar 27. [Epub  ahead of print].

15.  Bagonza J, Rutebemberwa E, Mugaga M, Tumuhamye N, Makumbi I. Yellow fever vaccination coverage following massive emergency immunization campaigns in rural Uganda, May 2011: a community cluster survey. BMC Public Health. 2013 Mar 7; 13:202.

16.  Baillie L. Can one size fit all? Towards a universal anthrax vaccine. Future  Microbiol. 2013 Mar; 8:295-7.

17.  Basili M, Ferrini S, Montomoli E. Swine influenza and vaccines: an alternative approach for decision making about pandemic prevention. Eur J Public  Health. 2013 Mar 26. [Epub ahead of print].

18.  Bejon P, White MT, Olotu A, Bojang K, Lusingu JP, Salim N, Otsyula NN, Agnandji ST, Asante KP, Owusu-Agyei S, Abdulla S, Ghani AC. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet  Infect Dis. 2013 Apr;13(4):319-27..

19.  Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, Xu H, Pascual V, Banchereau J, Garcia-Sastre A, Palucka AK, Ramilo O, Ueno H. Induction of ICOS+CXCR3+CXCR5+ TH  Cells Correlates with Antibody Responses to Influenza Vaccination. Sci Transl Med. 2013 Mar 13;5(176):176ra32.  

20.  Bonhoeffer J, Imoukhuede B, Aldrovandi G, Bachtiar NS, Chan ES, Chang S, Chen RT, Fernandopulle R, Goldenthal KL, Heffelfinger JD, Hossain S, Jevaji I, Khamesipour A, Kochhar S, Makhene M, Malkin E, Nalin D, Prevots R, Ramasamy R, Sellers S, Vekemans J, Walker B, Wilson P, Wong V, Zaman K, Heininger U; for the  Brighton Collaboration Clinical Trial Protocol Working Group. Template protocol for clinical trials investigating vaccines-Focus on safety elements. Vaccine. 2013 Mar 11. [Epub ahead of print].

21.  Bonnal C, Desaint C, Raynaud-Simon A, Fossey-Diaz V, Gougeon ML, Lucet JC, Launay O. [The vaccination of older adults: A challenge for the future!]. Presse  Med. 2013 Mar;42(3):318-26.

22.  Borja-Tabora C, Montalban C, Memish ZA, Van der Wielen M, Bianco V, Boutriau  D, Miller J. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid  conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis. 2013 Mar 5;13:116.

23.  Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness  analysis. Expert Rev Pharmacoecon Outcomes Res. 2013 Mar 28. [Epub ahead of print].

24.  Buricchi F, Bardelli M, Malzone C, Capecchi B, Nicolay U, Fragapane E, Castellino F, Del Giudice G, Galli G, Finco O. Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus. Eur J Immunol. 2013 Mar; 43(3):641-8.

25.  Caini S, Beck NS, Yacouba H, Maiga I, Chaibou I, Hinsa I, Adakal A, Issoufou  A, Kim SH, Pezzoli L. From Agadez to Zinder: estimating coverage of the MenAfriVacTM conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012. Vaccine. 2013 Mar 15; 31(12):1597-603.

26.  Campos-Outcalt D. Vaccine update: The latest from ACIP. J Fam Pract. 2013 Mar; 62(3):137-44.

27.  Cantu J, Biggio J, Jauk V, Wetta L, Andrews W, Tita A. Selective uptake of influenza vaccine and pregnancy outcomes. J Matern Fetal Neonatal Med. 2013 Mar 19. [Epub ahead of print].

28.  Carlton CA, Sienko DG, Vranesich PA. Seasonal influenza and Tdap vaccination  policies in Michigan hospitals: progress yet substantial capacity to improve. Infect Control Hosp Epidemiol. 2013 Mar; 34(3):321-4.

29.  Carvalho LM, de Paula FE, Silvestre RV, Roberti L, Arruda E, Mello WA, Ferriani VP. Prospective surveillance study of acute respiratory infections, influenza-like illness and seasonal influenza vaccine in a cohort of juvenile idiopathic arthritis patients. Pediatr Rheumatol Online J. 2013 Mar 7; 11(1):10. [Epub ahead of print].

30.  Cassidy B, Braxter B, Charron-Prochownik D, Schlenk EA. A Quality Improvement Initiative to Increase HPV Vaccine Rates Using an Educational and Reminder Strategy With Parents of Preteen Girls. J Pediatr Health Care. 2013 Mar 19. [Epub ahead of print].

31.  Castilla J, Godoy P, Domínguez A, Martínez-Baz I, Astray J, Martín V, Delgado-Rodríguez M, Baricot M, Soldevila N, Mayoral JM, Quintana JM, Galán JC, Castro A, González-Candelas F, Garín O, Saez M, Tamames S, Pumarola T; the CIBERESP Cases and Controls in Influenza Working Group. Influenza vaccine effectiveness in preventing out-patient, in-patient and severe cases of laboratory-confirmed influenza. Clin Infect Dis. 2013 Mar 26. [Epub ahead of print].

32.  Cerami C, Corbo M, Piccolo G, Iannaccone S. Autoimmune neuromyotonia following human papilloma virus vaccination. Muscle Nerve. 2013 Mar; 47(3):466-7.  

33.  Chan TC, Hung IF, Luk JK, Shea YF, Chan FH, Woo PC, Chu LW. Functional status of older nursing home residents can affect the efficacy of influenza vaccination. J Gerontol A Biol Sci Med Sci. 2013 Mar;68(3):324-30.

34.  Chavant F, Ingrand I, Jonville-Bera AP, Plazanet C, Gras-Champel V, Lagarce L, Zenut M, Disson-Dautriche A, Logerot S, Auffret M, Coubret-Dumas A, Bruel ML,  Boyer M, Bos-Thompson MA, Veyrac G, Carlier P, Beyens MN, Lates S, Damase-Michel  C, Castot A, Kreft-Jaïs C, Pérault-Pochat MC. The PREGVAXGRIP Study: a Cohort Study to Assess Foetal and Neonatal Consequences of In Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza. Drug Saf. 2013 Mar 21. [Epub ahead of print].

35.  Chiappini E, Stival A, Galli L, de Martino M. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis. 2013 Mar 26;13(1):151. [Epub ahead of print].

36.  Chiba N, Morozumi M, Shouji M, Wajima T, Iwata S, Sunakawa K, Ubukata And The Invasive Pneumococcal Diseases Surveillance Study Group K. Rapid Decrease of 7-Valent Conjugate Vaccine Coverage for Invasive Pneumococcal Diseases in Pediatric Patients in Japan. Microb Drug Resist. 2013 Mar 12. [Epub ahead of print].

37.  Clarke C, Wall GC, Soltis DA. An introductory pharmacy practice experience to improve pertussis immunization rates in mothers of newborns. Am J Pharm Educ. 2013 Mar 12;77(2):29.

38.  Clarke ET, Williams NA, Dull PM, Findlow J, Borrow R, Finn A, Heyderman RS. Polysaccharide-protein conjugate vaccination induces antibody production but not  sustained B-cell memory in the human nasopharyngeal mucosa. Mucosal Immunol. 2013 Mar; 6(2):288-96.

39.  Corace K, Prematunge C, McCarthy A, Nair RC, Roth V, Hayes T, Suh KN, Balfour L, Garber G. Predicting influenza vaccination uptake among health care workers: What are the key motivators? Am J Infect Control. 2013 Mar 22. [Epub ahead of print].

40.  Coyne-Beasley T, Reiter PL, Liberty AC, Ford CA, Miles DR, Brewer NT. Awareness Is Not Enough: The Need to Increase Meningococcal Vaccine Uptake. Clin  Pediatr (Phila). 2013 Mar 28. [Epub ahead of print].

41.  Daly ER, Anderson L, Dreisig J, Dionne-Odom J. Decrease in Varicella Incidence Following Implementation of the 2-Dose Recommendation for Varicella Vaccine in New Hampshire. Pediatr Infect Dis J. 2013 Mar 27. [Epub ahead of print].

42.  Danziger-Isakov L, Kumar D; T Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am J Transplant. 2013 Mar; 13 Suppl 4:311-7.

43.  Darden PM, Thompson DM, Roberts JR, Hale JJ, Pope C, Naifeh M, Jacobson RM. Reasons for Not Vaccinating Adolescents: National Immunization Survey of Teens, 2008-2010. Pediatrics. 2013 Mar 18. [Epub ahead of print].

44.  Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N. Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135  and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial. Drugs Aging. 2013 Mar 14. [Epub ahead of print].

45. de Whalley PC, Pollard AJ. Pandemic influenza A (H1N1) 2009 vaccination in children: A UK perspective. J Paediatr Child Health. 2013 Mar;49(3):E183-8.

46.  Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013 Mar 7. [Epub ahead of print].

47.  Domínguez A. [What do we learn from outbreaks of vaccine-preventable diseases?]. Gac Sanit. 2013 Mar;27(2):101-3.

48.  Douglas DL, Deroeck DA, Mahoney RT, Wichmann O. Will Dengue Vaccines Be Used  in the Public Sector and if so, How? Findings from an 8-country Survey of  Policymakers and Opinion Leaders. PLoS Negl Trop Dis. 2013 Mar;7(3):e2127.

49.  Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis. 2013 Mar 15;207(6):957-65.

50.  Elias J, Findlow J, Borrow R, Tremmel A, Frosch M, Vogel U. Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine. J Occup Med Toxicol. 2013 Mar 4;8(1):4.

51.  Fairbrother G, Donauer S, Staat MA, Broder K, Salisbury S, Morrow AL, Tabangin ME, Altaye M, Holloway M, Schwartz B. Cincinnati pediatricians' measured and reported immunizing behavior for children during the national shortages of pneumococcal conjugate vaccine. Vaccine. 2013 Mar 6. [Epub ahead of print].

52.  Falup-Pecurariu O, Leibovitz E, Mercas A, Bleotu L, Zavarache C, Porat N, Dagan R, Greenberg D. Pneumococcal acute otitis media in infants and children in  central Romania, 2009-2011: microbiological characteristics and potential coverage by pneumococcal conjugate vaccines. Int J Infect Dis. 2013 Mar 19. [Epub ahead of print].

53.  Finin P, Kosaraju A, Rose E, Rubin H. The role of vaccination, antiorthopoxvirus drug, and social cooperativity in a mathematical model of smallpox control. Biosecur Bioterror. 2013 Mar;11(1):59-72.

54.  Flannery B, Samad S, de Moraes JC, Tate JE, Danovaro-Holliday MC, de Oliveira LH, Rainey JJ. Uptake of oral rotavirus vaccine and timeliness of routine immunization in Brazil's National Immunization Program. Vaccine. 2013 Mar 1; 31(11):1523-8.

55.  Fowkes FJ, McGready R, Johnstone-Robertson S, Nosten F, Beeson JG. Antibody boosting and longevity following tetanus immunization during pregnancy. Clin Infect Dis. 2013 Mar; 56(5):749-50.

56.  Fox CB, Huynh C, O'Hara MK, Onu A. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Vaccine. 2013 Mar 15;31(12):1633-40.

57.  Francisco PM, Senicato C, Donalisio MR, Barros MB. [Rubella vaccination in women of childbearing age in Campinas, São Paulo State, Brazil]. Cad Saude Publica. 2013 Mar; 29(3):579-88.

58.  Gable KL, Afshari Z, Sufit RL, Allen JA. Distal acquired demyelinating symmetric neuropathy after vaccination. J Clin Neuromuscul Dis. 2013 Mar; 14(3):117-22.

59.  Gao J, Chen E, Wang Z, Shen J, He H, Ma H, Zeng G, Zhu BP. Epidemic of measles following the nationwide mass immunization campaign. BMC Infect Dis. 2013 Mar 18;13:139.

60.  García-Sastre A, Mena I. Novel vaccine strategies against emerging viruses. Curr Opin Virol. 2013 Mar 7. [Epub ahead of print].

61.  Gardam M, Lemieux C. Mandatory influenza vaccination? First we need a better  vaccine. CMAJ. 2013 Mar 25. [Epub ahead of print].

62.  Gastañaduy PA, Sánchez-Uribe E, Esparza-Aguilar M, Desai R, Parashar UD, Patel M, Richardson V. Effect of Rotavirus Vaccine on Diarrhea Mortality in Different Socioeconomic Regions of Mexico. Pediatrics. 2013 Mar 4. [Epub ahead of print].

63.  Gautret P, Parola P. Intradermal Route for Rabies Vaccination Should Be Generalized in Travelers. Clin Infect Dis. 2013 Mar 13. [Epub ahead of print].

64.  Gilbert SC. No easy route to a pandemic influenza vaccine. Lancet Infect Dis. 2013 Mar;13(3):188-9.

65.  Gilliland SM, Jenkins A, Parker L, Somdach N, Pattamadilok S, Incomserb P, Berry N, Schepelmann S, Minor P. Vaccine-related mumps infections in Thailand and the identification of a novel mutation in the mumps fusion protein. Biologicals.  2013 Mar;41(2):84-7.

66.  Golekoh MC, Hu S, Norman AM, Horn PS, Brady RC, Wong BL. Comparison of the Immunogenicity of Intramuscular Versus Subcutaneous Administration of Trivalent Inactivated Influenza Vaccine in Individuals With Neuromuscular Diseases. J Child Neurol. 2013 Mar 12. [Epub ahead of print].

67.  Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age. Vaccine. 2013 Mar 13. [Epub ahead of print].

68.  Grabenstein JD, O'Brien MA, Chen J. Cost-effectiveness of adult pneumococcal  vaccination: Responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44. Vaccine. 2013 Mar 15; 31(12):1549.

69.  Greenwood B. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine. 2013 Mar 1;31(11):1453-7.

70.  Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13.

71.  Griffin M, Makris M. Vaccination induced neutropenia. Int J Lab Hematol. 2013 Mar 22. [Epub ahead of print].

72.  Grimaldi-Bensouda L, Aubrun E, Leighton P, Benichou J, Rossignol M, Abenhaim  L; PGRx Study Group. Agreement between patients' self-report and medical records  for vaccination: the PGRx database. Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):278-85.

73.  Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza:  a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis. 2013 Mar;13(3):238-50.

74.  Gómez MM, Silva MF, Zeller M, Heylen E, Matthijnssens J, Ichihara MY, Rose TL, Volotão ED, Leite JP. Phylogenetic analysis of G1P[6] group A rotavirus strains detected in Northeast Brazilian children fully vaccinated with RotarixTM.  Infect Genet Evol. 2013 Mar 25. [Epub ahead of print].

75.  Haensler J. [Introduction to novel vaccine adjuvants and their role in influenza vaccination]. Ann Pharm Fr. 2013 Mar;71(2):104-8.

76.  Hak E, Shea KM, Jick SS. Association of infant pneumococcal vaccination with  pneumococcal pneumonia among mothers: A nested case-control study using the GPRD. Vaccine. 2013 Mar 15;31(12):1590-6.

77.  Harjaningrum AT, Kartasasmita C, Orne-Gliemann J, Jutand MA, Goujon N, Koeck  JL. A qualitative study on knowledge, perceptions, and attitudes of mothers and health care providers toward pneumococcal conjugate vaccine in Bandung, West Java, Indonesia. Vaccine. 2013 Mar 1; 31(11):1516-22.

78.  Hau M, Schwartz KL, Frenette C, Mogck I, Gubbay JB, Severini A, Hiebert J, Deeks SL, Morris SK. Local public health response to vaccine-associated measles:  case report. BMC Public Health. 2013 Mar 25;13(1):269. [Epub ahead of print].

79.  Hicks SS, Paul SP, Zengeya ST, Williams GM. Invasive Meningococcal Disease: The Need for Immunization in Childhood. Indian J Pediatr. 2013 Mar 24. [Epub ahead of print].

80.  Hofman R, van Empelen P, Vogel I, Raat H, van Ballegooijen M, Korfage IJ. Parental Decisional Strategies Regarding HPV Vaccination Before Media Debates: A  Focus Group Study. J Health Commun. 2013 Mar 22. [Epub ahead of print].

81.  Hofstetter AM, Natarajan K, Martinez RA, Rabinowitz D, Vawdrey DK, Stockwell  MS. Influenza vaccination coverage and timeliness among children requiring two doses, 2004-2009. Prev Med. 2013 Mar;56(3-4):165-70.

82.  Hoke CH Jr, Snyder CE Jr. History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. Vaccine. 2013 Mar 15;31(12):1623-32.

83.  Huang Q, Li D, Kang A, An W, Fan B, Ma X, Ma G, Su Z, Hu T. PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine. J Control Release. 2013 Mar 17. [Epub ahead of print].

84.  Huang WT, Yang HW, Liao TL, Wu WJ, Yang SE, Chih YC, Chuang JH. Safety of Pandemic (H1N1) 2009 Monovalent Vaccines in Taiwan: A Self-Controlled Case Series Study. PLoS One. 2013;8(3):e58827. doi: 10.1371/journal.pone.0058827. Epub 2013 Mar 11. PubMed PMID:

85.  Hutubessy R. Q&A - Economic analyses for vaccine introduction decisions in low- and middle- income countries. BMC Med. 2013 Mar 14;11:71.

86.  Idoko OT, Kochhar S, Agbenyega TE, Ogutu B, Ota MO. Impact, challenges, and  future projections of vaccine trials in Africa. Am J Trop Med Hyg. 2013 Mar;88(3):414-9.

87.  Jackson ML. Challenges in comparing the safety of different vaccination schedules. Vaccine. 2013 Mar 5. [Epub ahead of print].

88.  Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013 Mar 13. [Epub ahead of print].

89.  Jain KM, Paul P, Lamontagne DS. Monitoring adverse events following immunisation in developing countries: experience from human papillomavirus vaccination demonstration projects. Sex Health. 2013 Mar;10(1):57-63.

90.  Jarris P, Dolen V. Section 317 immunization program: protecting a national asset. Public Health Rep. 2013 Mar; 128(2):96-8.

91.  Jennings AR, Burant CJ. Influenza vaccination knowledge and perceptions among Veterans Affairs nurses. Am J Infect Control. 2013 Mar 19. [Epub ahead of print].

92.  Jentes ES, Han P, Gershman MD, Rao SR, Larocque RC, Staples JE, Ryan ET; the Global TravEpiNet Consortium. Travel Characteristics and Yellow Fever Vaccine Usage Among US Global TravEpiNet Travelers Visiting Countries with Risk of Yellow Fever Virus Transmission, 2009-2011. Am J Trop Med Hyg. 2013 Mar 4. [Epub ahead of print].

93.  Joung SM, Jeon SJ, Lim YJ, Lim JS, Choi BS, Choi IY, Yu JH, Na KI, Cho EH, Shin SS, Park YK, Kim CK, Kim HJ, Ryoo SW. Complete Genome Sequence of Mycobacterium bovis BCG Korea, the Korean Vaccine Strain for Substantial Production. Genome Announc. 2013 Mar 14;1(2):e0006913.

94.  Kang HY, Kim KH, Kim JH, Kim HM, Kim J, Kim MS, El Khoury AC, Kim DS. Economic evaluation of the national immunization program of rotavirus vaccination for children in Korea. Asia Pac J Public Health. 2013 Mar;25(2):145-58.

95.  Karron RA, Thumar B, Schappell E, Buchholz UJ, Collins PL. Attenuation of Live Respiratory Syncytial Virus Vaccines Is Associated With Reductions in Levels of Nasal Cytokines. J Infect Dis. 2013 Mar 26. [Epub ahead of print].

96.  Kay NE, Bainbridge TW, Condit RC, Bubb MR, Judd RE, Venkatakrishnan B, McKenna R, D'Costa SM. Biochemical and Biophysical Properties of a Putative Hub Protein Expressed by Vaccinia Virus. J Biol Chem. 2013 Mar 8. [Epub ahead of print].

97.  Kelvin DJ, Farooqui A. Extremely low vaccine effectiveness against influenza H3N2 in the elderly during the 2012/2013 flu season. J Infect Dev Ctries. 2013 Mar 14;7(3):299-301.

98.  Ketterer F, Goffin Y, Boyer P, Freyens A, Sourbes A, Belche JL, Giet D. [Criteria of the patient's decision concerning vaccination against influenza AH1N1, in Belgium and France]. Presse Med. 2013 Mar;42(3):e63-8.

99. Kim D, Lauria DT, Poulos C, Dong B, Whittington D. Effect of travel distance on household demand for typhoid vaccines: implications for planning. Int J Health Plann Manage. 2013 Mar 12. [Epub ahead of print].

100. Kosten T, Domingo C, Orson F, Kinsey B. Vaccines against stimulants: Cocaine and Methamphetamine. Br J Clin Pharmacol. 2013 Mar 19. [Epub ahead of print].

101. Kothare SV, Wiznitzer M. Association between H1N1 vaccination and narcolepsy-cataplexy: Flu to sleep. Neurology. 2013 Mar 13. [Epub ahead of print].

102. Kurstak E. Eighth World Congress on Vaccines, Immunisation and Immunotherapy. Hum Vaccin Immunother. 2013 Mar 1;9(3). [Epub ahead of print].

103. Kurzątkowski W, Kartoğlu U, Staniszewska M, Górska P, Krause A, Wysocki MJ.  Structural damages in adsorbed vaccines affected by freezing. Biologicals. 2013 Mar;41(2):71-6.

104. Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales. Clin Infect Dis. 2013 Mar;56(5):633-40.

105. Lau D, Eurich DT, Majumdar SR, Katz A, Johnson JA. Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax. 2013 Mar 27. [Epub ahead of print].

106. Hong Kong Rotarix Study Group, Lau YL, Nelson EA, Poon KH, Chan PK, Chiu S,  Sung R, Leung CW, Ng D, Ma YM, Chan D, Lee TL, Tang J, Kwan YW, Ip P, Ho M, Fung  LW, Tang H, Suryakiran PV, Han HH, Bock H. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: A randomized, controlled trial. Vaccine. 2013 Mar 13. [Epub ahead of print].

107. Ledgerwood JE. AS03-adjuvanted influenza vaccine in elderly people. Lancet Infect Dis. 2013 Mar 18. [Epub ahead of print].

108. Leung DT, Uddin T, Xu P, Aktar A, Johnson RA, Rahman MA, Alam MM, Bufano MK, Eckhoff G, Wu-Freeman Y, Yu Y, Sultana T, Khanam F, Saha A, Chowdhury F, Khan AI, Charles RC, Larocque RC, Harris JB, Calderwood SB, Kovác P, Qadri F, Ryan ET. Immune responses to the O-specific polysaccharide antigen in children receiving a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol. 2013 Mar 20. [Epub ahead of print].

109. Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, Young C, Netterlid E, Sparén P, Arnheim-Dahlström L. Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study. J Natl Cancer Inst. 2013 Mar 13. [Epub ahead of print].

110. Liesenborghs L, Verhaegen J, Peetermans WE, Vandeven J, Flamaing J. Trends in serotype prevalence in invasive pneumococcal disease before and after infant pneumococcal vaccination in Belgium, 2002-2010. Vaccine. 2013 Mar 1;31(11):1529-34.

111. Lim J, Choi B, Kim J, Kim J, Kim C, Park J, Yoon H, Hong S, Seo J, Ki M. Evaluation and sensitivity analysis of the effectiveness of unadjuvanted A(H1N1)pdm09 vaccine in hospital workers using multi-center cohort study in Korea. Vaccine. 2013 Mar 11. [Epub ahead of print].

112. Lindsey B, Kampmann B, Jones C. Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis. 2013 Mar 15. [Epub ahead of print].

113. Lo YC, Chuang JH, Kuo HW, Huang WT, Hsu YF, Liu MT, Chen CH, Huang HH, Chang CH, Chou JH, Chang FY, Lin TY, Chiu WT. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza b/yamagata-lineage viruses in taiwan, 2011-12 season. PLoS One. 2013;8(3):e58222.

114. Lopez P, Caicedo Y, Sierra A, Tilman S, Clemens R, Banzhoff A. Combined Administration of MF59(R)-Adjuvanted A/H5N1 Pre-Pandemic and Seasonal Influenza Vaccines: Long-Term Antibody Persistence and Robust Booster Responses One Year After a One-Dose Priming Schedule. Clin Vaccine Immunol. 2013 Mar 27. [Epub ahead of print].

115. Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the Expanded Programme on Immunization in Africa: Looking beyond 2015. PLoS Med. 2013 Mar;10(3):e1001405.

116. Macintosh VH, Tastad KJ, Eick-Cost AA. Mid-season influenza vaccine effectiveness 2011-2012: A Department of Defense Global, Laboratory-based, Influenza Surveillance System case-control study estimate. Vaccine. 2013 Mar 25;31(13):1651-5.

117. Maidens C, Childs C, Przemska A, Dayel IB, Yaqoob P. Modulation of vaccine response by concomitant probiotic administration. Br J Clin Pharmacol. 2013 Mar; 75(3):663-70.

118. Malagón T, Joumier V, Boily MC, Van de Velde N, Drolet M, Brisson M. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: A model-based analysis. Vaccine. 2013 Mar 25;31(13):1740-7.

119. Mangal S, Pawar D, Agrawal U, Jain AK, Vyas SP. Evaluation of mucoadhesive carrier adjuvant: Toward an oral anthrax vaccine. Artif Cells Nanomed Biotechnol. 2013 Mar 1. [Epub ahead of print].

120. Maradei E, Malirat V, Beascoechea CP, Benitez EO, Pedemonte A, Seki C, Novo  SG, Balette CI, D'Aloia R, La Torre JL, Mattion N, Toledo JR, Bergmann IE. Characterization of a type O foot-and-mouth disease virus re-emerging in the year 2011 in free areas of the Southern Cone of South America and cross-protection studies with the vaccine strain in use in the region. Vet Microbiol. 2013 Mar 23;162(2-4):479-90.

121. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, Perez JL. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013 Mar 15; 31(12):1569-75.

122. Martínez-Baz I, Martínez-Artola V, Reina G, Guevara M, Cenoz MG, Morán J, Irisarri F, Arriazu M, Albeniz E, Castilla J; Primary Health Care Sentinel Network of Navarre. Effectiveness of the trivalent influenza vaccine in Navarre,  Spain, 2010-2011: a population-based test-negative case-control study. BMC Public Health. 2013 Mar 6; 13:191.

123. Martínez-Flórez G, Bolfarine H, Gómez HW. Asymmetric regression models with  limited responses with an application to antibody response to vaccine. Biom J. 2013 Mar; 55(2):156-72.

124. Mason JN, Elbahesh H, Russell CJ. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based HPIV3 vaccines. J Virol. 2013 Mar 20. [Epub ahead of print].

125. Mastelic B, Lewis DJ, Golding H, Gust I, Sheets R, Lambert PH. Potential use of inflammation and early immunological event biomarkers in assessing vaccine safety. Biologicals. 2013 Mar; 41(2):115-24.

126. Matsuo K, Hirobe S, Okada N, Nakagawa S. Frontiers of transcutaneous vaccination systems: Novel technologies and devices for vaccine delivery. Vaccine. 2013 Mar 20. [Epub ahead of print].

127. McAuliffe K, Peddecord KM, Wang W, Ralston K, Deguire M, Waters-Montijo K, Sawyer MH. Influenza vaccination and its association with clinic use of evidence-based practices and individual patient characteristics, San Diego County, 2009. J Public Health Manag Pract. 2013 Mar-Apr;19(2):178-86.

128. McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L; for the  Influence65 study group. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013 Mar 18. [Epub ahead of print].

129. Melo Gomes S, Glover M, Malone M, Brogan P. Vasculitis following HPV immunization. Rheumatology (Oxford). 2013 Mar; 52(3):581-2.

130. Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ. Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis. Value Health. 2013 Mar-Apr; 16(2):311-7.

131. Miles M, Ryman TK, Dietz V, Zell E, Luman ET. Validity of vaccination cards  and parental recall to estimate vaccination coverage: A systematic review of the  literature. Vaccine. 2013 Mar 15;31(12):1560-8.

132. Mollica A, Stefanucci A, Costante R. Strategies for Developing Tuberculosis  Vaccines: Emerging Approaches. Curr Drug Targets. 2013 Mar 6. [Epub ahead of print].

133. Mongua-Rodriguez N, Díaz-Ortega JL, García-García L, Piña-Pozas M, Ferreira-Guerrero E, Delgado-Sánchez G, Ferreyra-Reyes L, Cruz-Hervert LP, Baez-Saldaña R, Campos-Montero R. A systematic review of rubella vaccination strategies implemented in the Americas: impact on the incidence and seroprevalence rates of rubella and congenital rubella syndrome. Vaccine. 2013 Mar 5. [Epub ahead of print].

134. Moorthy V, Newman R, Duclos P, Okwo-Bele J, Smith P. Assessment of the RTS,S/AS01 malaria vaccine. Lancet Infect Dis. 2013 Apr;13(4):280-2.

135. Morandi M, Sali M, Manganelli R, Delogu G. Exploiting the mycobacterial cell wall to design improved vaccines against tuberculosis. J Infect Dev Ctries. 2013  Mar 14;7(3):169-81.

136. Mp B, L P, S F, J B, N C. Human Papillomavirus Vaccine Knowledge and Uptake  among Adolescent Boys and Girls in an Appalachian Ohio County. Cancer Epidemiol Biomarkers Prev. 2013 Mar; 22(3):473-4.

137. Muhammad RD, Oza-Frank R, Zell E, Link-Gelles R, Narayan KM, Schaffner W, Thomas A, Lexau C, Bennett NM, Farley MM, Harrison LH, Reingold A, Hadler J, Beall B, Klugman KP, Moore MR. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis. 2013 Mar; 56(5):e59-67.

138. Myers MG. Vaccination to prevent varicella. Vaccine. 2013 Mar 25;31(13):1695.

139. Nakayama T, Sawada A, Kubo H, Kaida A, Tanaka T, Shigemoto N, Komase K, Takeda M. Simple method for differentiating measles vaccine from wild-type strains using loop-mediated isothermal amplification. Microbiol Immunol. 2013 Mar; 57(3):246-51.

140. National Vaccine Advisory Committee. Protecting the Public's Health: Critical Functions of the Section 317 Immunization Program-A Report of the National Vaccine Advisory Committee. Public Health Rep. 2013 Mar;128(2):78-95.

141. Nisar MK, Ostor AJ. TNF antagonists and shingles: is vaccination advisable?  Ann Rheum Dis. 2013 Mar 1. [Epub ahead of print].

142. O'Leary ST, Allison MA, Stokley S, Crane LA, Hurley LP, Beaty B, Kempe A. Physicians' confidence in vaccine safety studies. Prev Med. 2013 Mar;56(3-4):231-3.

143. Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, Duncan CJ, Collins KA, Garcia Knight MA, Kimani E, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Spencer AJ, Soipei P, Mueller J, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Gantlett K, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Urban BC, Flanagan KL, Ewer KJ, Chilengi R, Hill AV, Bojang K. Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. PLoS One. 2013;8(3):e57726.

144. Oncel S, Alvur M. How reliable is the Internet for caregivers on their decision to vaccinate their child against influenza? Results from googling in two languages. Eur J Pediatr. 2013 Mar;172(3):401-4. 

145. Opel DJ, Marcuse EK. The enigma of alternative childhood immunization schedules: what are the questions? JAMA Pediatr. 2013 Mar 1;167(3):304-5.

146. Orson FM, Rossen RD, Shen X, Lopez AY, Wu Y, Kosten TR. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict. 2013 Mar-Apr;22(2):169-74.

147. Ostergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis. 2013 Mar; 17(3):e173-6.

148. Oviedo-Orta E, Plotkin SA, Ulmer JB, Ahmed SS. Therapeutic vaccines and immunotherapies: current challenges and new frontiers. Expert Rev Vaccines. 2013  Mar;12(3):243-4.

149. Payne DC, Boom JA, Staat MA, Edwards KM, Szilagyi PG, Klein EJ, Selvarangan  R, Azimi PH, Harrison C, Moffatt M, Johnston SH, Sahni LC, Baker CJ, Rench MA, Donauer S, McNeal M, Chappell J, Weinberg GA, Tasslimi A, Tate JE, Wikswo M, Curns AT, Sulemana I, Mijatovic-Rustempasic S, Esona MD, Bowen MD, Gentsch JR, Parashar UD. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years old, 2009-2011. Clin Infect Dis. 2013 Mar 13. [Epub ahead of print].

150. Perkins RB, Tipton H, Shu E, Marquez C, Belizaire M, Porter C, Clark JA, Pierre-Joseph N. Attitudes toward HPV vaccination among low-income and minority parents of sons: a qualitative analysis. Clin Pediatr (Phila). 2013 Mar;52(3):231-40.

151. Peña MT, Preciado D, Orestes M, Choi S. Orbital complications of acute sinusitis: changes in the post-pneumococcal vaccine era. JAMA Otolaryngol Head Neck Surg. 2013 Mar 1; 139(3):223-7.

152. Phonrat B, Pitisuttithum P, Chamnanchanunt S, Puthavathana P, Ngaosuwankul N, Louisirirotchanakul S, Dhitavat J, Thirapakpoomanunt S, Chokevivat V, Wibulpolprasert S. Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. Vaccine. 2013 Mar 1;31(11):1503-9.

153. Pichon B, Ladhani SN, Slack MP, Segonds-Pichon A, Andrews NJ, Waight PA, Miller E, George R. Changes in molecular epidemiology of streptococcus pneumonia causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. J Clin Microbiol. 2013 Mar;51(3):820-7.

154. Pichon S, Guinet-Morlot F, Minutello M, Donazzolo Y, Rouzier R, Chassard D,  Fitoussi S, Hou V. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine VerorabTM for pre-exposure use in healthy adults: Results from a randomized controlled phase-II trial. Vaccine. 2013 Mar 16. [Epub ahead of print].

155. Plotkin SA. Complex Correlates of Protection After Vaccination. Clin Infect  Dis. 2013 Mar 13. [Epub ahead of print].

156. Privileggio L, Falchi A, Grisoni ML, Souty C, Turbelin C, Fonteneau L, Hanslik T, Kernéis S. Rates of immunization against pandemic and seasonal influenza in persons at high risk of severe influenza illness: a cross-sectional  study among patients of the French Sentinelles general practitioners. BMC Public  Health. 2013 Mar 20; 13(1):246. [Epub ahead of print].

157. Pruitt CN, Reese CS, Grossardt BR, Shire AM, Creedon DJ. Completion of the Human Papillomavirus Vaccination Series Lags in Somali Adolescents. J Low Genit Tract Dis. 2013 Mar 12. [Epub ahead of print].

158. Rackoff LA, Bok K, Green KY, Kapikian AZ. Epidemiology and Evolution of Rotaviruses and Noroviruses from an Archival WHO Global Study in Children (1976-79) with Implications for Vaccine Design. PLoS One. 2013; 8(3):e59394.

159. Rahman MS. Estimating Vaccine Efficacy under the Heterogeneity of Vaccine Action in a Nonrandomly Mixing Population. J Biopharm Stat. 2013 Mar 11; 23(2):394-412.

160. Rebmann T, Elliott MB, Swick Z, Reddick D. US School Morbidity and Mortality, Mandatory Vaccination, Institution Closure, and Interventions Implemented During the 2009 Influenza A H1N1 Pandemic. Biosecur Bioterror. 2013 Mar;11(1):41-8.

161. Ribassin-Majed L, Lounes R, Clemençon S. Deterministic modelling for transmission of Human Papillomavirus 6/11: impact of vaccination. Math Med Biol.  2013 Mar 7. [Epub ahead of print].

162. Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, Bonfa E. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken).  2013 Mar; 65(3):476-80.

163. Rohner GB, Snape MD, Kelly DF, O'Connor D, Brar S, John T, Kibwana E, Parksm H, Ford K, Dull PM, Pollard AJ. Seroprevalence and Placental Transmission of Maternal Antibodies Specific for Neisseria meningitidis Serogroups A, C, Y and W135 and Influence of Maternal Antibodies on the Immune Response to a Primary Course of MenACWY-CRM Vaccine in the United Kingdom. Pediatr Infect Dis J. 2013 Mar 27. [Epub ahead of print].

164. Rouveix E, Greffe S, Dupont C, Gherissi Cherni D, Beauchet A, Sordet Guepet  H, Gavazzi G, Gaillat J; Intergroupe Société de pathologie infectieuse de langue  française/Société de gériatrie et gérontologie clinique (Spilf/SGGC). [Low vaccination coverage against influenza in elderly hospitalized in France.]. Rev Med Interne. 2013 Mar 5. [Epub ahead of print].

165. Ruiz-Aragón J, Grande Tejada AM, Márquez-Peláez S, Molina Linde JM, Yang R.  [Assessment of the MF59-adjuvanted pandemic influenza A/H1N1 vaccine. Systematic  review of literature.]. An Pediatr (Barc). 2013 Mar 12. [Epub ahead of print].

166. Rustomjee R, McClain B, Brennan MJ, McLeod R, Chetty-Makkan CM, McShane H, Hanekom W, Steel G, Mahomed H, Ginsberg AM, Shea J, Lockhart S, Self S, Churchyard GJ. Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents.  Tuberculosis (Edinb). 2013 Mar;93(2):136-42.

167. Saitoh A, Nagata S, Saitoh A, Tsukahara Y, Vaida F, Sonobe T, Kamiya H, Naruse T, Murashima S. Perinatal immunization education improves immunization rates and knowledge: A randomized controlled trial. Prev Med. 2013 Mar 20. [Epub ahead of print].

168. Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, Cunningham F, Garman P, Greene SK, Lee GM, Vellozzi C, Yih WK, Gellin B, Lurie N; the H1N1 GBS Meta-Analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA:  a meta-analysis. Lancet. 2013 Mar 12. [Epub ahead of print].

169. Schiffer JM, Maniatis P, Garza I, Steward-Clark E, Korman LT, Pittman PR, Mei JV, Quinn CP. Quantitative assessment of anthrax vaccine immunogenicity using the dried blood spot matrix. Biologicals. 2013 Mar;41(2):98-103.

170. Schulze C. A 44-year-old patient with a new-onset seizure disorder after vaccination against Japanese encephalitis: a case report. J Med Case Rep. 2013 Mar 12;7(1):66. [Epub ahead of print].

171. Setchanova LP, Kostyanev T, Alexandrova AB, Mitov IG, Nashev D, Kantardjiev  T. Microbiological characterization of Streptococcus pneumoniae and non-typeable  Haemophilus influenzae isolates as primary causes of acute otitis media in Bulgarian children before the introduction of conjugate vaccines. Ann Clin Microbiol Antimicrob. 2013 Mar 25;12(1):6. [Epub ahead of print].

172. Singh Joy SD. Quadrivalent HPV Vaccine is Safe. Am J Nurs. 2013 Mar;113(3):66-7.

173. Skowronski DM, De Serres G, Janjua NZ, Hottes TS. Re: "effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy". Am J Epidemiol. 2013 Mar 15; 177(6):593-4.

174. Smit R. Response to "Limitations of the study 'Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults"'. Vaccine. 2013 Mar 20.  [Epub ahead of print].

175. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE Jr. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis. 2013 Mar 22. [Epub ahead of print].

176. Smits G, Mollema L, Hahné S, de Melker H, Tcherniaeva I, Waaijenborg S, van  Binnendijk R, van der Klis F, Berbers G. Seroprevalence of Mumps in The Netherlands: Dynamics over a Decade with High Vaccination Coverage and Recent Outbreaks. PLoS One. 2013; 8(3):e58234.

177. Soentjens P, Aerssens A, Van Gucht S, Ravinetto R, Van Gompel A. Low-Cost Intradermal Rabies Vaccination Is Indeed Very Promising. Clin Infect Dis. 2013 Mar 13. [Epub ahead of print].

178. Song JY, Cheong HJ, Heo JY, Noh JY, Seo YB, Kim IS, Choi WS, Kim WJ. Outpatient-based pneumococcal vaccine campaign and survey of perceptions about pneumococcal vaccination in patients and doctors. Yonsei Med J. 2013 Mar 1;54(2):469-75.

179. Spertini F, Audran R, Lurati F, Ofori-Anyinam O, Zysset F, Vandepapelière P, Moris P, Demoitié MA, Mettens P, Vinals C, Vastiau I, Jongert E, Cohen J, Ballou  WR. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: A randomized controlled phase I/II study. Tuberculosis (Edinb). 2013 Mar; 93(2):179-88.

180. Stoof SP, Heijstek MW, Sijssens KM, van der Klis F, Sanders EA, Teunis PF, Wulffraat NM, Berbers GA. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. Ann Rheum Dis. 2013 Mar 16. [Epub ahead of print].

181. Strachan RE, Snelling TL, Jaffé A. Increased paediatric hospitalizations for empyema in Australia after introduction of the 7-valent pneumococcal conjugate vaccine. Bull World Health Organ. 2013 Mar 1;91(3):167-73.

182. Sume GE, Fouda AA, Kobela M, Nguelé S, Emah I, Atem P. A locally initiated and executed measles outbreak response immunization campaign in the nylon health  district, Douala Cameroon 2011. BMC Res Notes. 2013 Mar 16;6:100.

183. Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, Gibbons RV, Fernandez S, Gunther VJ, Mammen MP Jr, Statler JD, Innis BL. Experimental dengue  virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis. 2013 Mar 1;207(5):700-8.

184. Tacke CE, Smits GP, van der Klis FR, Kuipers IM, Zaaijer HL, Kuijpers TW. Reduced serologic response to mumps, measles, and rubella vaccination in patients treated with intravenous immunoglobulin for Kawasaki disease. J Allergy Clin Immunol. 2013 Mar 13. [Epub ahead of print].

185. Takeuchi M, Yasunaga H, Horiguchi H, Fushimi K. The burden of epiglottitis among Japanese children before the Haemophilus influenzae type b vaccination era: an analysis using a nationwide administrative database. J Infect Chemother. 2013  Mar 20. [Epub ahead of print].

186. Talbot TR, Talbot HK. Influenza prevention update: examining common arguments against influenza vaccination. JAMA. 2013 Mar 6; 309(9):881-2.

187. Tavares F, Cheuvart B, Heineman T, Arellano F, Dubin G. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine. Vaccine. 2013 Mar 25; 31(13):1759-64.

188. Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM. Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). Risk Anal. 2013 Mar 7. [Epub ahead of print].

189. Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM.  Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine-Related Polioviruses. Risk Anal. 2013 Mar 22. [Epub ahead of print].

190. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL. Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control. Risk Anal. 2013 Mar 5. [Epub ahead of print].

191. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and Validation of a Plaque Reduction Neutralization Test for the Detection of Neutralizing Antibodies to Four Serotypes of Dengue Virus Used in Support of Dengue Vaccine Development. Am J Trop Med Hyg. 2013 Mar 4. [Epub ahead of print].

192. Timmermans K, Plantinga TS, Kox M, Vaneker M, Scheffer GJ, Adema GJ, Joosten LA, Netea MG. Blueprints of Signaling Interactions between Pattern Recognition Receptors: Implications for the Design of Vaccine Adjuvants. Clin Vaccine Immunol. 2013 Mar; 20(3):427-32.

193. Togashi T, Yamaji M, Thompson A, Giardina PC, Aizawa M, Patterson S, Gruber  WC, Scott DA. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan. Pediatr Infect Dis J. 2013 Mar 27. [Epub ahead of print].

194. Touma Z, Gladman DD, Urowitz MB. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Curr Opin Rheumatol. 2013 Mar; 25(2):164-70.

195. Traynor K. First recombinant flu vaccine approved. Am J Health Syst Pharm. 2013 Mar 1;70(5):382.

196. Treanor JJ, Szilagyi P. Influenza Vaccine: Glass Half Full or Half Empty? Clin Infect Dis. 2013 Mar 5. [Epub ahead of print].

197. Upreti SR, Janusz KB, Schluter WW, Bichha RP, Shakya G, Biggerstaff BJ, Shrestha MM, Sedai TR, Fischer M, Gibbons RV, Shrestha SK, Hills SL. Estimation of the Impact of a Japanese Encephalitis Immunization Program with Live, Attenuated SA 14-14-2 Vaccine in Nepal. Am J Trop Med Hyg. 2013 Mar; 88(3):464-468.

198. Van Buynder PG, Frosst G, Van Buynder JL, Tremblay FW, Ross A, Jardine C, Fei BG. Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination. Influenza Other Respi Viruses. 2013 Mar; 7(2):184-90.

199. van Duin D. Vaccines, 6th Edition. Clin Infect Dis. 2013 Mar 13. [Epub ahead of print].

200. van Lier A, van de Kassteele J, de Hoogh P, Drijfhout I, de Melker H. Vaccine uptake determinants in The Netherlands. Eur J Public Health. 2013 Mar 26. [Epub ahead of print].

201. Vanhaecke Collard C, Novella JL, Mahmoudi R. Influenza and pneumococcal vaccine coverage among patients admitted to an acute geriatric unit. Geriatr Psychol Neuropsychiatr Vieil. 2013 Mar 1; 11(1):7-14.

202. Velan B, Boyko V, Shenhar G, Lerner-Geva L, Kaplan G. Analysis of public responses to preparedness policies: the cases of H1N1 influenza vaccination and gas mask distribution. Isr J Health Policy Res. 2013 Mar 27; 2(1):11. [Epub ahead  of print].

203. Ventura R, Brunner L, Heriyanto B, de Boer O, O'Hara M, Huynh C, Suhardono M, Collin N. Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. Vaccine. 2013 Mar 15; 31(12):1641-5.

204. Verguet S, Jassat W, Bertram MY, Tollman SM, Murray CJ, Jamison DT, Hofman KJ. Supplementary immunization activities (SIAs) in South Africa: comprehensive economic evaluation of an integrated child health delivery platform. Glob Health  Action. 2013 Mar 1; 6:1-9.

205. Viviani S. A vaccine to prevent epidemic meningitis in Africa. Lancet Infect Dis. 2013 Mar; 13(3):195-6.

206. Wahed T, Kaukab SS, Saha NC, Khan IA, Khanam F, Chowdhury F, Saha A, Khan AI, Siddik AU, Cravioto A, Qadri F, Uddin J. Knowledge of, attitudes toward, and  preventive practices relating to cholera and oral cholera vaccine among urban high-risk groups: findings of a cross-sectional study in Dhaka, Bangladesh. BMC Public Health. 2013 Mar 19; 13:242. doi: 10.1186/1471-2458-13-242.

207. Wang IK, Lin CL, Lin PC, Liang CC, Liu YL, Chang CT, Yen TH, Morisky DE, Huang CC, Sung FC. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PLoS One. 2013;8(3):e58317.

208. Wells CR, Klein EY, Bauch CT. Policy resistance undermines superspreader vaccination strategies for influenza. PLoS Comput Biol. 2013 Mar; 9(3):e1002945.

209. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced Risk of Pertussis Among Persons Ever Vaccinated With Whole Cell Pertussis Vaccine Compared to Recipients of Acellular Pertussis Vaccines in a Large US Cohort. Clin Infect Dis. 2013 Mar 13. [Epub ahead of print].

210. Wiwanitkit V. Guillain-barré syndrome after influenza vaccination. J Clin Neuromuscul Dis. 2013 Mar;14(3):126.

211. Wiysonge CS, Uthman OA, Ndumbe PM, Hussey GD. A bibliometric analysis of childhood immunization research productivity in Africa since the onset of the Expanded Program on Immunization in 1974. BMC Med. 2013 Mar 14;11:66. doi: 10.1186/1741-7015-11-66. PubMed PMID:

212. Wu DB, Rinaldi F, Huang YC, Chang JA, Chang CJ. Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: A cost-effectiveness analysis. J Formos Med Assoc. 2013 Mar; 112(3):151-60.

213. Yoo BK, Humiston SG, Szilagyi PG, Schaffer SJ, Long C, Kolasa M. Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial. Vaccine. 2013 Mar 13. [Epub ahead of print].

214. Zhao Z, Smith PJ. Trends in vaccination coverage disparities among children, United States, 2001-2010. Vaccine. 2013 Mar 21. [Epub ahead of print].

215. Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax(®)) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip(®)) to adults aged ≥60 years: An open-label, randomised trial. Vaccine. 2013 Mar 1; 31(11):1496-502.

216. Zlamy M, Kofler S, Orth D, Würzner R, Heinz-Erian P, Streng A, Prelog M. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis.  2013 Mar 1; 13:112.